Eli Lilly and Company (LLY.SW)
| Previous close | 690.00 |
| Open | 690.00 |
| Bid | 655.00 x 0 |
| Ask | 785.00 x 0 |
| Day's range | 690.00 - 690.00 |
| 52-week range | 384.00 - 740.00 |
| Volume | |
| Avg. volume | 1,664 |
| Market cap | 655.779B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 111.11 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.56 (0.66%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- Yahoo Finance
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
- Yahoo Finance Video
Weight-loss drug competition heats up. Is Wegovy in trouble?
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
- Yahoo Finance
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
